{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T09:27:18Z","timestamp":1758274038069,"version":"3.44.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 108-2314-B-039-007-MY3","MOST 110-2314-B-A49A-534"],"award-info":[{"award-number":["MOST 108-2314-B-039-007-MY3","MOST 110-2314-B-A49A-534"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V110C-158"],"award-info":[{"award-number":["V110C-158"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.bbrc.2021.09.078","type":"journal-article","created":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T05:25:47Z","timestamp":1633065947000},"page":"137-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Affibody-conjugated 5-fluorouracil prodrug system preferentially targets and inhibits HER2-expressing cancer cells"],"prefix":"10.1016","volume":"582","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1575-5620","authenticated-orcid":false,"given":"Keng-Hsueh","family":"Lan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4154-0110","authenticated-orcid":false,"given":"Cheng-Liang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tun-Ling","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiung-Wen","family":"Pai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yee","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keng-Li","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2021.09.078_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2017.06.005","article-title":"Evolution of anti-HER2 therapies for cancer treatment","volume":"59","author":"Parakh","year":"2017","journal-title":"Canc. Treat Rev."},{"key":"10.1016\/j.bbrc.2021.09.078_bib2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13058-021-01459-y","article-title":"Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions","volume":"23","author":"Ferraro","year":"2021","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bbrc.2021.09.078_bib3","first-page":"10615","article-title":"Treatment landscape for patients with HER2-positive metastatic breast cancer: a review on emerging treatment options","volume":"12","author":"Gampenrieder","year":"2020","journal-title":"Canc. Manag. Res."},{"key":"10.1016\/j.bbrc.2021.09.078_bib4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/jac\/46.2.171","article-title":"Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions","volume":"46","author":"Vermes","year":"2000","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.bbrc.2021.09.078_bib5","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jmb.2010.03.002","article-title":"Design of an optimized scaffold for affibody molecules","volume":"398","author":"Feldwisch","year":"2010","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.bbrc.2021.09.078_bib6","article-title":"Microbial enzymes used in prodrug activation for cancer therapy: insights and future perspectives","author":"Dhankhar","year":"2020","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.bbrc.2021.09.078_bib7","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1002\/jcp.26094","article-title":"Mesenchymal stem cells: a new platform for targeting suicide genes in cancer","volume":"233","author":"Moradian Tehrani","year":"2018","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.bbrc.2021.09.078_bib8","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.mt.6300190","article-title":"The suicide gene therapy challenge: how to improve a successful gene therapy approach","volume":"15","author":"Bonini","year":"2007","journal-title":"Mol. Ther. : the journal of the American Society of Gene Therapy"},{"key":"10.1016\/j.bbrc.2021.09.078_bib9","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.trecan.2019.12.010","article-title":"Trastuzumab emtansine: mechanisms of action and resistance, clinical progress, and beyond","volume":"6","author":"Garcia-Alonso","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bbrc.2021.09.078_bib10","first-page":"1417","article-title":"Superiority of yeast over bacterial cytosine deaminase for enzyme\/prodrug gene therapy in colon cancer xenografts","volume":"59","author":"Kievit","year":"1999","journal-title":"Canc. Res."},{"key":"10.1016\/j.bbrc.2021.09.078_bib11","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/protein\/gzn028","article-title":"Engineering of a femtomolar affinity binding protein to human serum albumin","volume":"21","author":"Jonsson","year":"2008","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.bbrc.2021.09.078_bib12","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/nbt1364","article-title":"Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C","volume":"25","author":"Subramanian","year":"2007","journal-title":"Nat. Biotechnol."},{"issue":"Suppl 4","key":"10.1016\/j.bbrc.2021.09.078_bib13","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/S0049-3848(08)70029-X","article-title":"Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa","volume":"122","author":"Schulte","year":"2008","journal-title":"Thromb. Res."},{"key":"10.1016\/j.bbrc.2021.09.078_bib14","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/bip.22474","article-title":"A\u00a0GLP-1 receptor agonist conjugated to an albumin-binding domain for extended half-life","volume":"102","author":"Lindgren","year":"2014","journal-title":"Biopolymers"},{"key":"10.1016\/j.bbrc.2021.09.078_bib15","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1007\/s00018-013-1370-9","article-title":"Development and characterization of small bispecific albumin-binding domains with high affinity for ErbB3","volume":"70","author":"Nilvebrant","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bbrc.2021.09.078_bib16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ijbiomac.2021.07.080","article-title":"The development of human serum albumin-based drugs and relevant fusion proteins for cancer therapy","volume":"187","author":"Tao","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bbrc.2021.09.078_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.addr.2018.07.011","article-title":"Harnessing albumin as a carrier for cancer therapies","volume":"130","author":"Hoogenboezem","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbrc.2021.09.078_bib18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00280-019-03850-1","article-title":"Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin((R))) in patients with HER2-positive metastatic breast cancer","volume":"84","author":"Chen","year":"2019","journal-title":"Canc. Chemother. Pharmacol."},{"key":"10.1016\/j.bbrc.2021.09.078_bib19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/jlcr.3465","article-title":"Preparation and preclinical evaluation of (131) I-trastuzumab for breast cancer","volume":"60","author":"Kameswaran","year":"2017","journal-title":"J.\u00a0Label. Compd. Radiopharm."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X2101384X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X2101384X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T12:12:01Z","timestamp":1757765521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X2101384X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":19,"alternative-id":["S0006291X2101384X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2021.09.078","relation":{},"ISSN":["0006-291X"],"issn-type":[{"type":"print","value":"0006-291X"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Affibody-conjugated 5-fluorouracil prodrug system preferentially targets and inhibits HER2-expressing cancer cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2021.09.078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}